[go: up one dir, main page]

RU2000120951A - Transdermal Therapy System (TSS) Containing Antioxidant - Google Patents

Transdermal Therapy System (TSS) Containing Antioxidant

Info

Publication number
RU2000120951A
RU2000120951A RU2000120951/14A RU2000120951A RU2000120951A RU 2000120951 A RU2000120951 A RU 2000120951A RU 2000120951/14 A RU2000120951/14 A RU 2000120951/14A RU 2000120951 A RU2000120951 A RU 2000120951A RU 2000120951 A RU2000120951 A RU 2000120951A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
antioxidant
amount
tocopherol
ethyl
Prior art date
Application number
RU2000120951/14A
Other languages
Russian (ru)
Other versions
RU2219926C2 (en
Inventor
Бодо АСМУССЕН
Михаэль ХОРСШТМАНН
Кай Кепке
Харри ТИЕМЕССЕН
Original Assignee
Новартис Аг
Лтс Ломанн Терапи-Системе Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9800526.7A external-priority patent/GB9800526D0/en
Application filed by Новартис Аг, Лтс Ломанн Терапи-Системе Аг filed Critical Новартис Аг
Publication of RU2000120951A publication Critical patent/RU2000120951A/en
Application granted granted Critical
Publication of RU2219926C2 publication Critical patent/RU2219926C2/en

Links

Claims (13)

1. Фармацевтическая композиция, включающая (S)-N-этил-3-[1-диметиламино)этил] -N-метилфенилкарбамат (соединение А) в форме свободного основания или в форме кислотно-аддитивной соли и антиоксидант.1. A pharmaceutical composition comprising (S) -N-ethyl-3- [1-dimethylamino) ethyl] -N-methylphenylcarbamate (compound A) in the form of a free base or in the form of an acid addition salt and an antioxidant. 2. Фармацевтическая композиция по п. 1, включающая 1-40 мас. % соединения А в форме свободного основания или в форме кислотно-аддитивной соли. 2. The pharmaceutical composition according to claim 1, comprising 1-40 wt. % of compound A in the form of a free base or in the form of an acid addition salt. 3. Фармацевтическая композиция по п. 1 или 2, в которой антиоксидант представляет собой токоферол, его сложные эфиры, аскорбиновую кислоту, бутилгидрокситолуол, бутилгидроксианизол или пропилгаллат, аскорбилпальмитат, предпочтительно α-токоферол или аскорбилпальмитат. 3. The pharmaceutical composition of claim 1 or 2, wherein the antioxidant is tocopherol, esters, ascorbic acid, butylhydroxytoluene, butylhydroxyanisole or propyl gallate, ascorbyl palmitate, preferably α-tocopherol or ascorbyl palmitate. 4. Фармацевтическая композиция по любому из предыдущих пунктов, в которой антиоксидант присутствует в количестве от примерно 0,01 до примерно 0,5 мас. % в пересчете на массу фармацевтической композиции. 4. The pharmaceutical composition according to any one of the preceding paragraphs, in which the antioxidant is present in an amount of from about 0.01 to about 0.5 wt. % based on the weight of the pharmaceutical composition. 5. Фармацевтическая композиция по любому из предыдущих пунктов, в которой антиоксидант токоферол присутствует в количестве 0,1 мас. % в пересчете на массу фармацевтической композиции. 5. The pharmaceutical composition according to any one of the preceding paragraphs, in which the antioxidant tocopherol is present in an amount of 0.1 wt. % based on the weight of the pharmaceutical composition. 6. Фармацевтическая композиция по п. 1, включающая а) соединение А в форме свободного основания в количестве 20-40 мас. %, б) полиметакрилат в количестве 10-30 мас. %, в) сополимер акрилата в количестве 40-60 мас. % и г) α-токоферол в количестве 0,05-0,3 мас. %, где общая масса фармацевтической композиции принята за 100%. 6. The pharmaceutical composition according to claim 1, comprising a) compound A in the form of a free base in an amount of 20-40 wt. %, b) polymethacrylate in an amount of 10-30 wt. %, c) acrylate copolymer in an amount of 40-60 wt. % and g) α-tocopherol in an amount of 0.05-0.3 wt. %, where the total weight of the pharmaceutical composition is taken as 100%. 7. Применение антиоксиданта для стабилизации фармацевтической композиции, содержащей соединение А. 7. The use of an antioxidant to stabilize a pharmaceutical composition containing compound A. 8. Применение по п. 7, где антиоксидант представляет собой токоферол, его сложные эфиры, аскорбиновую кислоту, бутилгидрокситолуол, бутилгидроксианизол или пропилгаллат, предпочтительно α-токоферол или аскорбилпальмитат. 8. The use of claim 7, wherein the antioxidant is tocopherol, esters, ascorbic acid, butylhydroxytoluene, butylhydroxyanisole or propyl gallate, preferably α-tocopherol or ascorbyl palmitate. 9. Применение по п. 7 или 8, где антиоксидант присутствует в количестве от примерно 0,01 до примерно 0,5 мас. % в пересчете на массу фармацевтической композиции. 9. The use of claim 7 or 8, wherein the antioxidant is present in an amount of from about 0.01 to about 0.5 wt. % based on the weight of the pharmaceutical composition. 10. Применение по любому из пп. 7-9, где антиоксидант токоферол присутствует в количестве 0,1 мас. % в пересчете на массу фармацевтической композиции. 10. The use according to any one of paragraphs. 7-9, where the antioxidant tocopherol is present in an amount of 0.1 wt. % based on the weight of the pharmaceutical composition. 11. Трансдермальное устройство для введения фармацевтической композиции по любому из пп. 1-6. 11. A transdermal device for administering a pharmaceutical composition according to any one of claims. 1-6. 12. Трансдермальное устройство, включающее фармацевтическую композицию по п. 1, защитный слой, являющийся подложкой для фармацевтической композиции, адгезив для контакта и фиксации фармацевтической композиции к защитному слою и разъединяющую прокладку, при отсутствии контакта которой с этим адгезивом она может быть отделена. 12. A transdermal device comprising the pharmaceutical composition according to claim 1, a protective layer that is a substrate for the pharmaceutical composition, adhesive for contacting and fixing the pharmaceutical composition to the protective layer, and a release liner, in the absence of contact with which this adhesive can be separated. 13. Трансдермальное устройство, включающее защитный слой, слой, содержащий (S)-N-этил-3-[1-диметиламино)этил] -N-метилфенилкарбамат в полимерной матрице, разъединяющую прокладку и расположенный между слоем, содержащим (S)-N-этил-3-[1-диметиламино)этил] -N-метилфенилкарбамат в полимерной матрице, и разъединяющей прокладкой дискретный слой адгезивного материала, предназначенный для фиксации этого трандермального устройства на коже пациента с возможностью последующего отделения от кожи. 13. A transdermal device comprising a protective layer, a layer containing (S) -N-ethyl-3- [1-dimethylamino) ethyl] -N-methylphenylcarbamate in a polymer matrix, separating the spacer and located between the layer containing (S) -N -ethyl-3- [1-dimethylamino) ethyl] -N-methylphenylcarbamate in a polymer matrix, and a release liner, a discrete layer of adhesive material designed to fix this transdermal device on the patient's skin with the possibility of subsequent separation from the skin.
RU2000120951/15A 1998-01-12 1999-01-08 Antioxidant-containing percutaneous therapeutic system RU2219926C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9800526.7A GB9800526D0 (en) 1998-01-12 1998-01-12 Organic compounds
GB9800526.7 1998-01-12

Publications (2)

Publication Number Publication Date
RU2000120951A true RU2000120951A (en) 2002-08-10
RU2219926C2 RU2219926C2 (en) 2003-12-27

Family

ID=10825116

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000120951/15A RU2219926C2 (en) 1998-01-12 1999-01-08 Antioxidant-containing percutaneous therapeutic system

Country Status (25)

Country Link
US (1) US6335031B1 (en)
EP (1) EP1047409B1 (en)
KR (1) KR100569051B1 (en)
CN (1) CN1129427C (en)
AT (1) ATE223711T1 (en)
AU (1) AU745661B2 (en)
BR (1) BR9906920A (en)
CA (1) CA2315784C (en)
CZ (1) CZ300598B6 (en)
DE (1) DE69902875T2 (en)
DK (1) DK1047409T3 (en)
ES (1) ES2184408T3 (en)
GB (1) GB9800526D0 (en)
HU (1) HU227159B1 (en)
ID (1) ID27503A (en)
IL (1) IL137100A (en)
MX (1) MXPA00006438A (en)
NO (1) NO328390B1 (en)
NZ (1) NZ505650A (en)
PL (1) PL201328B1 (en)
PT (1) PT1047409E (en)
RU (1) RU2219926C2 (en)
SK (1) SK284622B6 (en)
TR (2) TR200001688T2 (en)
WO (1) WO1999034782A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL196945B1 (en) 1998-10-01 2008-02-29 Novartis Ag New sustained release oral formulations
FR2793689B1 (en) * 1999-05-19 2001-08-24 Pf Medicament TRANSDERMAL DEVICE FOR THE ADMINISTRATION OF TESTOSTERONE OR A DERIVATIVE THEREOF
ATE245972T1 (en) * 1999-11-29 2003-08-15 Lohmann Therapie Syst Lts TRANSDERMAL THERAPEUTIC SYSTEMS WITH IMPROVED STABILITY AND A METHOD FOR THE PRODUCTION THEREOF
DE10107663B4 (en) * 2001-02-19 2004-09-09 Lts Lohmann Therapie-Systeme Ag Testosterone-containing transdermal therapeutic system, process for its preparation and its use
ITMI20020798A1 (en) * 2002-04-15 2003-10-15 F T Holding S A SILICONE ADHESIVE MATERIAL TRANSDERMAL PATCHES STABILIZED WITH METHACRYLIC COPOLYMERS
FR2881653A1 (en) * 2005-02-04 2006-08-11 Frederic Khodja Device for continuous administration of a controlled amount of an active agent comprising mineral or vitamin, useful e.g. in protecting chemical complexes in the cells, comprises a transcutaneous adhesive stamp containing active agent
TWI389709B (en) 2005-12-01 2013-03-21 Novartis Ag Transdermal therapeutic system
WO2009022345A1 (en) * 2007-08-14 2009-02-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Phenyl carbamates for the treatment of multiple sclerosis
UA103332C2 (en) * 2008-07-28 2013-10-10 Такеда Фармасьютикал Компани Лимитед Pharmaceutical composition containing a nonpeptidic active agent having a primary or secondary amino group
US20100087768A1 (en) * 2008-10-02 2010-04-08 Forlano Paula Transdermal drug delivery system for liquid active ingredient
EP2515886B1 (en) 2009-12-22 2018-04-11 Luye Pharma AG Transdermal therapeutic system for administering rivastigmine or derivatives thereof
US10076502B2 (en) 2009-12-22 2018-09-18 Luye Pharma Ag Transdermal therapeutic system for administering rivastigmine or derivatives thereof
ES2363395B1 (en) * 2010-01-20 2012-02-23 Farmalider, S.A. PHARMACEUTICAL COMPOSITION L�? QUIDA DE RIVASTIGMINA OR ONE OF ITS ADDITION SALES OF �? CIDO FOR ADMINISTRATION BY ORAL.
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
DE102010026903A1 (en) 2010-07-12 2012-01-12 Amw Gmbh Transdermal therapeutic system with avocado oil or palm oil as adjuvant
ES2720952T3 (en) 2010-07-21 2019-07-25 3M Innovative Properties Co Transdermal adhesive compositions, devices and methods
PL2468274T3 (en) 2010-12-14 2015-11-30 Luye Pharma Ag Transdermal therapeutic system for application of an agent
KR101788802B1 (en) * 2010-12-24 2017-10-20 주식회사 삼양바이오팜 Percutaneous absorption preparation containing rivastigmine
KR20120126898A (en) * 2011-05-13 2012-11-21 에스케이케미칼주식회사 Transdermal composition comprising rivastigmine or its salt
KR20120130073A (en) * 2011-05-20 2012-11-28 에스케이케미칼주식회사 Patch comprising rivastigmine
JP6017543B2 (en) 2011-05-20 2016-11-02 エスケー ケミカルズ カンパニー, リミテッドSk Chemicals Co., Ltd. Rivastigmine-containing patch
EP2594261A1 (en) 2011-11-18 2013-05-22 Labtec GmbH Composition for transdermal administration of rivastigmine
DE102012000369A1 (en) 2012-01-11 2013-07-11 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermal therapeutic system with cholinesterase inhibitor
WO2013142339A1 (en) 2012-03-23 2013-09-26 Novartis Ag Transdermal therapeutic system and method
US10758494B2 (en) 2012-06-12 2020-09-01 KM Transderm Ltd. Rivastigmine-containing adhesive patch
JP6269488B2 (en) * 2012-09-03 2018-01-31 ニプロ株式会社 Patch
KR20140038237A (en) 2012-09-20 2014-03-28 에스케이케미칼주식회사 Medical product showing improved stability of rivastigmine
US9895320B2 (en) 2012-09-28 2018-02-20 KM Transderm Ltd. Transdermal patch with different viscosity hydrocarbon oils in the drug layer and the adhesive layer
WO2014111790A2 (en) 2013-01-15 2014-07-24 Zydus Technologies Limited Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
CN106413695B (en) * 2014-04-08 2019-12-10 帝国制药美国公司 Rivastigmine transdermal compositions and methods of use thereof
JPWO2015174502A1 (en) 2014-05-15 2017-05-25 ニチバン株式会社 Packaging for patches containing rivastigmine
KR102823139B1 (en) 2018-08-31 2025-06-19 에스케이케미칼 주식회사 Rivastigmine patch for long-term administration
KR102710072B1 (en) 2018-08-31 2024-09-24 에스케이케미칼 주식회사 Rivastigmine patch for long-term administration
KR20220143065A (en) * 2020-02-19 2022-10-24 스미토모 파마 가부시키가이샤 Transdermal Absorption Formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL195004C (en) * 1987-03-04 2003-11-04 Novartis Ag Pharmaceutical preparation containing phenyl carbamate.
GB9213322D0 (en) * 1992-06-23 1992-08-05 Efamol Holdings Antioxidant compositions
WO1998030243A1 (en) * 1997-01-08 1998-07-16 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
DE69802498T2 (en) * 1997-01-17 2002-07-04 Takeda Chemical Industries, Ltd. COMBINATION PRODUCT CONTAINING IDEBENON FOR ALZHEIMER TREATMENT

Similar Documents

Publication Publication Date Title
RU2000120951A (en) Transdermal Therapy System (TSS) Containing Antioxidant
RU2219926C2 (en) Antioxidant-containing percutaneous therapeutic system
US20200289426A1 (en) Transdermal Therapeutic System for Administering an Active Substance
JP5806287B2 (en) Transdermal delivery patch
HUE035312T2 (en) Pharmaceutical patch for transdermal administration of (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine
KR100267442B1 (en) Percutaneous administration system for the treatment of thrombosis and prevention of cancer containing acetylsalicylic acid
BR0109198B1 (en) Plaster having a backing
US20130261571A1 (en) Transdermal Therapeutic System For Administering Rivastigmine Or Derivatives Thereof
ES2230872T3 (en) TRANSDERMAL PATCH THAT CONTAINS AT LEAST AN ACTIVE PRINCIPLE THAT INFLUENCES THE LEVELS OF LIPIDS IN BLOOD.
US6316023B1 (en) TTS containing an antioxidant
ES2897449T3 (en) Transparent transdermal therapeutic system containing nicotine
WO2014111790A2 (en) Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
HU220045B (en) Suitable for the controlled release of pilocarpine is a transdermal system and method
JP2022543537A (en) Acrylic polymer and adhesive composition
JPH0742228B2 (en) Pharmaceutical formulation
JPH06183956A (en) Stable pharmaceutical preparation for application
AU4905699A (en) Therapeutic system with addition of nacreous pigments
BR112019017151B1 (en) TRANSDERMAL THERAPEUTIC SYSTEM, METHOD FOR PRODUCING THE SAME, USE OF A POLYMER AND METHOD FOR STABILIZING NICOTINE
HK1034036B (en) Tts containing an antioxidant